In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.

doi:10.1136/jitc-2024-011070

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.

Journal for immunotherapy of cancer - 5 Jun 2025

Zelba Henning, Shao Borong, Rabsteyn Armin, Reinhardt Annekathrin, Greve Carsten, Oenning Lisa, Kayser Simone, Kyzirakos Christina, Latzer Pauline, Riedlinger Tabea, Bartsch Oliver, Wünsche Julian, Harter Johannes, Feldhahn Magdalena, Bantel Yannick, Johänning Janina, Ködding Jiri, Hadaschik Dirk, Schulze Martin, Battke Florian, Maksimovic Olga, Scheble Veit, Miller Alexandra M, Castro Michael, Blumenthal Deborah T, Glas Martin, Reardon David, Biskup Saskia

Abstract excerpt

Isocitrate dehydrogenase (IDH) mutant glioma is a malignant primary brain tumor diagnosed in adults. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors. The first targeted IDH-inhibitor was approved by the US Food and Drug Administration in August 2024 for grade 2 gliomas, in light of results of a phase III trial which showed significant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Neoplasm

Share to Brain Neoplasms

Share to Cancer Vaccines

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Precision Medicine

Share to Vaccines, Subunit

Source

Open in PubMed Open full text

Identifiers

PMID: 40480654
DOI: 10.1136/jitc-2024-011070
PMCID: PMC12142095

Genes

CD4
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.PMID 40480654Read ↗

A vaccine targeting mutant IDH1 in newly diagnosed glioma.Semantic proximity Read ↗

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.Semantic proximity Read ↗

A vaccine targeting mutant IDH1 induces antitumour immunity.Semantic proximity Read ↗

Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma.Semantic proximity Read ↗

Computational Identification of Clonal Neoantigens in IDH-Wildtype Glioblastoma Through Integrated Genomic Filtering and HLA PredictionSemantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trialsSemantic proximity Read ↗

A Specific Peptide Vaccine Against IDH1(R132H) Glioma.Semantic proximity Read ↗

Synthetic multiepitope neoantigen DNA vaccine for personalized cancer immunotherapy.Semantic proximity Read ↗

Automating neoantigen selection for personalized cancer vaccine designSemantic proximity Read ↗

Personalized vaccines for cancer immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.